HC Wainwright & Co. Maintains Buy on Immunovant, Raises Price Target to $27
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao maintains a Buy rating on Immunovant (NASDAQ:IMVT) and raises the price target from $26 to $27.

May 23, 2023 | 4:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Immunovant and raises the price target from $26 to $27.
The raised price target by HC Wainwright & Co. analyst Douglas Tsao indicates a positive outlook for Immunovant's stock. This news is likely to have a positive short-term impact on the stock price as it shows increased confidence in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100